F/m Emerald Life Sciences Innovation ETF (LFSC) Performance
LFSC total return
Distributions reinvested · as of Oct 23, 2026- YTD
- +13.6% since Dec 31, 2025
- 1 year
- +35.5% total return
- Since first price
- +66.4% since 2024
LFSC trailing returns vs SPY, QQQ, AGG
| Period | LFSC total return | Price only | S&P 500 (SPY) | Nasdaq-100 (QQQ) | U.S. bonds (AGG) |
|---|---|---|---|---|---|
| 1 month | −6.1% | −6.1% | −1.0% | −5.0% | +0.9% |
| 3 months | −8.5% | −8.5% | +3.2% | +1.9% | −0.4% |
| 6 months | +11.6% | +11.6% | +7.8% | +8.4% | −1.5% |
| YTD | +13.6% | +13.6% | +12.3% | +15.1% | −1.0% |
| 1 year | +35.5% | +35.5% | +14.4% | +15.9% | −1.1% |
| Since inceptionOct 21, 2024 | +66.4% | +66.4% | — | — | — |
Total return from adjusted closes (distributions reinvested, before tax). Periods of 3 years or more are also shown annualized. Price only excludes distributions.
Growth of $10,000: LFSC vs SPY
From Oct 21, 2024: LFSC grew to $16,637, SPY to $13,322.
Year-end values with distributions reinvested, no taxes or trading costs. Start: first common trading day of both funds.
LFSC returns by calendar year
1 of 1 full years positive. Best 2025 (+56.5%), worst 2025 (+56.5%). 2026 is year to date.
LFSC annual returns table
| Year | LFSC | Largest drop | SPY | QQQ | AGG |
|---|---|---|---|---|---|
| 2026YTD | +13.6% | −17.6% | +12.3% | +15.1% | −1.0% |
| 2025 | +56.5% | −28.0% | +17.7% | +20.8% | +7.2% |
Largest drop = deepest fall from a high within that calendar year.
Calendar-year return vs largest drop within the year
Most years include a sizable fall at some point even when the year ends higher.
LFSC largest drawdowns
Now 14.1% below the high| Peak | Decline | Bottom | Recovered | Fall | Underwater |
|---|---|---|---|---|---|
| Nov 11, 2024 | −29.7% | Apr 8, 2025 | Aug 22, 2025 | 5 months | 9 months |
| Aug 19, 2026 | −17.6% | Oct 16, 2026 | not yet | 58 days | 2 months so far |
| Dec 10, 2025 | −16.2% | Mar 30, 2026 | May 28, 2026 | 4 months | 6 months |
Declines from a closing high (distributions reinvested) of 10% or more. Underwater = time from the peak until the old high was regained.
LFSC risk statistics
| Statistic | Since 2024 |
|---|---|
| Annualized return | +35.5% |
| Volatility (annualized) | 26.3% |
| Sharpe ratio | 1.14 |
| Sortino ratio | 2.36 |
| Best month | +15.3% |
| Worst month | −11.3% |
| Best 12 months | +88.0% |
| Worst 12 months | +32.1% |
| Positive months | 61% |
| Beta vs S&P 500 | — |
| Correlation with S&P 500 | — |
From monthly total returns. Sharpe and Sortino use 1–3 month T-bills (BIL) as the risk-free rate, so they need history from 2007 on.
LFSC rolling returns
| Holding period | Periods | Worst | Median | Best | Positive |
|---|---|---|---|---|---|
| 1-year | 13 | +26.5% | +55.8% | +88.0% | 100% |
Every holding period starting at a month-end since 2024. Returns for 3 years and longer are annualized.
LFSC performance overview
F/m Emerald Life Sciences Innovation ETF (LFSC) returned +35.5% over the past year, with distributions reinvested. Since its first recorded price on Oct 21, 2024 it has returned +66.4%. Over the same year S&P 500 (SPY) returned +14.4%.
The deepest decline was −29.7%, from Nov 11, 2024 to Apr 8, 2025, and it took 4 months to get back to the old high. Volatility has been 26.3% a year.
Related: LFSC chart, LFSC holdings. See the LFSC overview for the latest quote and fund facts.
LFSC performance FAQ
What is the LFSC return over the past year?
LFSC returned +35.5% over the 12 months to October 23, 2026, including reinvested distributions. On price alone it rose 35.5%.
How much would $10,000 invested in LFSC be worth?
$10,000 invested in LFSC at its first recorded close on October 21, 2024 would be worth about $16,637 on October 23, 2026 with distributions reinvested.
What is the biggest drawdown of LFSC?
The largest peak-to-trough decline was −29.7% between November 11, 2024 and April 8, 2025. It recovered to the old high on August 22, 2025, 4 months after the bottom.
How volatile is LFSC?
Over the past history LFSC had an annualized volatility of 26.3% and a Sharpe ratio of 1.14 (excess return over 1–3 month T-bills per unit of risk).